|
|
|
|
|
Indomethacin
drug data and news
Indomethacin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Indomethacin | ||
| Brand Names/Synonyms | Amuno; Apo-Indomethacin; Argun; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Bonidon Gel; CCRIS 3502; Catlep; Chibro-Amuno; Chrono-Indicid; Chrono-Indocid; Confortid; Dolcidium; Dolcidium Pl; Dolovin; Durametacin; Elmetacin; Flexin Continus; HSDB 3101; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indo-Lemmon; Indo-Phlogont; Indo-Rectolmin; Indo-Spray; Indo-Tablinen; Indocid; Indocid Pda; Indocid Sr; Indocin; Indocin I.V; Indocin I.V.; Indocin Sr; Indolar Sr; Indomecol; Indomed; Indomee; Indometacin; Indometacine; Indometacyna; Indomethacin; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Inteban Sp; Lausit; Liometacen [As Meglumine Salt]; Metacen; Metartril; Methazine; Metindol; Mezlin; Mezlocillin; Mezolin; Miametan; Mikametan; Mobilan; Novo-Methacin; Novomethacin; Nu-Indo; Reumacide; Rhemacin La; Rheumacin La; Sadoreum; Tannex; USAN; Vonum | ||
| Indication | For moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Indomethacin, a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. | ||
| Mechanism Of Action | Antiinflammatory effects of Indomethacin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. | ||
| Indomethacin News (When available) |
Roxane Laboratories, Inc. Announces the Launch of Fluticasone ... Feb 23, 2006 First Generic Version of Flonase Approved Feb 23, 2006 FDA Approves First Generic Version of Flonase Feb 22, 2006 FDA Approves Generic Version Of Flonase Nasal Spray Feb 23, 2006 First Generic of Glaxo's Flonase is Approved Feb 24, 2006 FDA approves generic version of popular allergy drug Flonase Feb 28, 2006 First Generic Version of Flonase Approved Feb 23, 2006 GSK blocks generic Flonase in USA, for now Feb 27, 2006 FDA OKs Generic Version of Flonase Feb 22, 2006 FDA Approves First Generic Form of Flonase Feb 23, 2006 GlaxoSmithKline blocks sales of competitor's generic Flonase Feb 27, 2006 GlaxoSmithKline blocks sales of generic competitor to its Flonase ... Feb 24, 2006 Par Pharmaceutical Reports Sales and Earnings for 2005 Feb 28, 2006 Generic Flonase Gets FDA OK Feb 23, 2006 Par Pharmaceutical Halts Shipment of Generic Flonase(R) Feb 24, 2006 Par Pharmaceutical Begins Shipment of Generic Flonase(R) Feb 23, 2006 Boehringer Ingelheim Announces 48-week Results from Aptivus(R) ... Feb 9, 2006 Generic Flonase blocked in court Feb 25, 2006 Par Pharma halts generic Flonase shipments after GSK wins ... Feb 24, 2006 National Briefing Feb 24, 2006 FDA approves generic Flonase spray Feb 24, 2006 Judge orders halt to sales of generic Flonase Feb 24, 2006 GlaxoSmithKline blocks sales of generic competitor to Flonase Feb 26, 2006 Lundergan group buys Continental Inn Feb 24, 2006 Generic nasal spray sales blocked Feb 25, 2006 Business notebook Feb 23, 2006 Cash relief in store for allergy sufferers Feb 24, 2006 Glaxo Loses US Court Bid to Block Generic Flonase (Update1) 06 Mar 2006 Roxane Laboratories, Inc. Announces the Launch of Fluticasone ... Feb 23, 2006 First Generic Version of Flonase Approved Feb 23, 2006 FDA Approves First Generic Version of Flonase Feb 22, 2006 FDA Approves Generic Version Of Flonase Nasal Spray Feb 23, 2006 First Generic of Glaxo's Flonase is Approved Feb 24, 2006 FDA approves generic version of popular allergy drug Flonase Feb 28, 2006 First Generic Version of Flonase Approved Feb 23, 2006 GSK blocks generic Flonase in USA, for now Feb 27, 2006 FDA OKs Generic Version of Flonase Feb 22, 2006 FDA Approves First Generic Form of Flonase Feb 23, 2006 GlaxoSmithKline blocks sales of competitor's generic Flonase Feb 27, 2006 GlaxoSmithKline blocks sales of generic competitor to its Flonase ... Feb 24, 2006 Par Pharmaceutical Reports Sales and Earnings for 2005 Feb 28, 2006 Generic Flonase Gets FDA OK Feb 23, 2006 Par Pharmaceutical Halts Shipment of Generic Flonase(R) Feb 24, 2006 Par Pharmaceutical Begins Shipment of Generic Flonase(R) Feb 23, 2006 Boehringer Ingelheim Announces 48-week Results from Aptivus(R) ... Feb 9, 2006 Generic Flonase blocked in court Feb 25, 2006 Par Pharma halts generic Flonase shipments after GSK wins ... Feb 24, 2006 National Briefing Feb 24, 2006 FDA approves generic Flonase spray Feb 24, 2006 Judge orders halt to sales of generic Flonase Feb 24, 2006 GlaxoSmithKline blocks sales of generic competitor to Flonase Feb 26, 2006 Lundergan group buys Continental Inn Feb 24, 2006 Generic nasal spray sales blocked Feb 25, 2006 Business notebook Feb 23, 2006 Cash relief in store for allergy sufferers Feb 24, 2006 | ||
| Dosage Forms | CAPSULE | ||
| Drug_Category | Tocolytic Agents; Cardiovascular Agents; Anti-inflammatory Agents; Nonsteroidal Antiinflammatory Agents (NSAIDs); ATC:S01BC; ATC:M01AB | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Indomethacin: In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin. In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage. Therefore, diflunisal and INDOCIN should not be used concomitantly. In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%. The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy. Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants. However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time. In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN. Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly. When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased. Therefore, a lower total daily dosage of INDOCIN may produce a satisfactory therapeutic effect. When increases in the dose of INDOCIN are made, they should be made carefully and in small increments. Caution should be used if INDOCIN is administered simultaneously with methotrexate. INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity. Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin. NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored. Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations. This effect has been attributed to inhibition of prostaglandin synthesis. As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity. (Read circulars for lithium preparations before use of such concomitant therapy.) In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment. INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored. In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics. Therefore, when INDOCIN and INDOCIN. (Indomethacin) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained. INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion. These facts should be considered when evaluating plasma renin activity in hypertensive patients. It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers. INDOCIN and triamterene should not be administered together. INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels. The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently. Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN. Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported. Therefore, when using these blocking agents to treat hypertension, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained. INDOCIN can reduce the antihypertensive effects of captopril and losartan. False-negative results in the dexamethasone suppression test (DST) in patients being treated with INDOCIN have been reported. Thus, results of the DST should be interpreted with caution in these patients. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]ethanoicacid | ||
| Chemical Formula | C19H16ClNO4 | ||
| Molecular Weight | 357.787 g/mol | ||
| Smiles String | CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O | ||
| Melting Point | 158 °C | ||
| Water Solubility | 0.937 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 3.655 | ||
| Isoelectric Point | 4.5 | ||
| Biotransformation | Not Available | ||
| Half Life | 4.5 hours | ||
| Protein Binding [%] | 97% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Indomethacin.html http://www.rxlist.com/cgi/generic/indometh.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00109 | ||
| CAS Registry Number | 53-86-1 | ||
| KEGG Compound ID | C01926 | ||
| PubChem ID | SID:148696 | ||
| PharmGKB ID | PA449982 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2143372 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |